Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the…

By J. Bellmunt, C. Théodore, T. Demkov, B. Komyakov, L. Sengeløv, G. Daugaard, A. Caty, J. Carles, A. Jagiełło-Gruszfeld, O. Karyakin and 7 more. Journal of Clinical Oncology, 2009

713 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/68b7a040817b4d13fa373dc51aa7f7be094960dc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Charles Dumontet
2. J. Luke
3. G. Colón-Otero
4. J. A. Blake-Haskins
5. M. Gordon
6. Sunil Sharma
7. M. Jordan
8. W. Tan

Citations in the corpus

• Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. (2016, background): “The ORR and durability of responses observed in patients with PD-L1–positive tumors (as defined by TC or IC expression using the SP263 assay) compares favorably with the outcomes provided with currently available therapies for this population.(6) The safety profile of durvalumab in patients with UBC”
• Microtubule-binding agents: a dynamic field of cancer therapeutics (2010, background): “Vinflunine , a novel fluorinated compound that was obtained by superacid transformation of vinorelbine in the presence of fluorhydric acid, has recently been approved for the second-line treatment of bladder cance”